Literature DB >> 889043

Retained antral mucosa in pancreaticoduodenectomy patients.

N Basso, M Simi, E Lezoche, S Giri, A Materia, S Leardi, V Speranza.   

Abstract

Thirteen patients with pancreaticoduodenectomy were studied. In three patients presenting with stomal ulcer or bleeding stomitis, endoscopic biopsies showed the presence of retained antral mucosa (RAM). No disease and no RAM was present in the remaining ten patients. Bombesin (BBS) infusion augmented both gastric acid and gastrin secretion in the group with RAM, whereas no change was apparent in the remaining ten patients. The BBS infusion test is useful in detecting stomal ulcer high risk pancreaticoduodenectomy patients.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 889043     DOI: 10.1016/0002-9610(77)90358-0

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  5 in total

1.  Studies with bombesin in man.

Authors:  N Basso; E Lezoche; V Speranza
Journal:  World J Surg       Date:  1979-09-20       Impact factor: 3.352

Review 2.  Is antisecretory therapy after pancreatoduodenectomy necessary? Meta-analysis and contemporary practices of pancreatic surgeons.

Authors:  James R Butler; Tyrone Rogers; George Eckart; Gregory R Martens; Eugene P Ceppa; Michael G House; Attila Nakeeb; C Max Schmidt; Nicholas J Zyromski
Journal:  J Gastrointest Surg       Date:  2015-02-18       Impact factor: 3.452

3.  Marginal Ulcer Perforation in a Whipple Survivor: A Rare Long-Term Complication.

Authors:  Arunraj P; Kolandasamy C; Prabhakaran R; Sugumar Chidambaranathan; Naganath Babu O L
Journal:  Cureus       Date:  2022-08-16

4.  Exocrine and endocrine stomach after gastrobulbar preserving pancreatoduodenectomy.

Authors:  H C Kim; T Suzuki; T Kajiwara; T Miyashita; M Imamura; T Tobe
Journal:  Ann Surg       Date:  1987-12       Impact factor: 12.969

5.  Normogastrinaemic gastric hypersecretion with recurrent and fistulating jejunal ulcer.

Authors:  P Rao; J H Baron; G Glazer
Journal:  J R Soc Med       Date:  1992-01       Impact factor: 18.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.